日本制药公司Sosei Heptares发现或可治疗COVID-19的小分子-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1794227, encodeId=435d1e94227f4, content=<a href='/topic/show?id=e6501655420' target=_blank style='color:#2F92EE;'>#Sosei#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16554, encryptionId=e6501655420, topicName=Sosei)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Apr 16 12:15:17 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914709, encodeId=e7c31914e096a, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sun Jun 27 03:15:17 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294588, encodeId=e212129458869, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591536, encodeId=c23e159153699, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903591, encodeId=2e9c903591b5, content=<a href='/topic/show?id=65b05806579' target=_blank style='color:#2F92EE;'>#新冠病毒#</a> <a href='/topic/show?id=d61d32384ef' target=_blank style='color:#2F92EE;'>#制药#</a> 日本制药公司Sosei早在4月就启动了研发计划，旨在设计和开发针对SARS-CoV-2病毒的新型药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=234, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58065, encryptionId=65b05806579, topicName=新冠病毒), TopicDto(id=32384, encryptionId=d61d32384ef, topicName=制药)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Mon Nov 30 17:10:00 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903287, encodeId=399990328e6b, content=想学习想学习想学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Nov 29 14:38:48 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903276, encodeId=7e479032e65e, content=打败新冠，共同进步。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/928bf083b196415cbaa5a8292d70e333/cdfe5f3f34794434be595ee70b8766e8.jpg, createdBy=69a95401355, createdName=ms9000001235733856, createdTime=Sun Nov 29 14:35:34 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903265, encodeId=05e390326555, content=希望有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/b5cbbe56f416461784f4cd3a1f07fac9/5dfb1f9c9f4c4d7f8d5f82b96a120488.jpg, createdBy=e4702774429, createdName=18327144a0m, createdTime=Sun Nov 29 14:12:18 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903233, encodeId=a8a4903233c1, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sun Nov 29 11:19:04 CST 2020, time=2020-11-29, status=1, ipAttribution=)]

2021-04-16 cqlidoudou

#Sosei#

77 0

[GetPortalCommentsPageByObjectIdResponse(id=1794227, encodeId=435d1e94227f4, content=<a href='/topic/show?id=e6501655420' target=_blank style='color:#2F92EE;'>#Sosei#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16554, encryptionId=e6501655420, topicName=Sosei)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Apr 16 12:15:17 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914709, encodeId=e7c31914e096a, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sun Jun 27 03:15:17 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294588, encodeId=e212129458869, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591536, encodeId=c23e159153699, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903591, encodeId=2e9c903591b5, content=<a href='/topic/show?id=65b05806579' target=_blank style='color:#2F92EE;'>#新冠病毒#</a> <a href='/topic/show?id=d61d32384ef' target=_blank style='color:#2F92EE;'>#制药#</a> 日本制药公司Sosei早在4月就启动了研发计划，旨在设计和开发针对SARS-CoV-2病毒的新型药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=234, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58065, encryptionId=65b05806579, topicName=新冠病毒), TopicDto(id=32384, encryptionId=d61d32384ef, topicName=制药)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Mon Nov 30 17:10:00 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903287, encodeId=399990328e6b, content=想学习想学习想学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Nov 29 14:38:48 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903276, encodeId=7e479032e65e, content=打败新冠，共同进步。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/928bf083b196415cbaa5a8292d70e333/cdfe5f3f34794434be595ee70b8766e8.jpg, createdBy=69a95401355, createdName=ms9000001235733856, createdTime=Sun Nov 29 14:35:34 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903265, encodeId=05e390326555, content=希望有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/b5cbbe56f416461784f4cd3a1f07fac9/5dfb1f9c9f4c4d7f8d5f82b96a120488.jpg, createdBy=e4702774429, createdName=18327144a0m, createdTime=Sun Nov 29 14:12:18 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903233, encodeId=a8a4903233c1, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sun Nov 29 11:19:04 CST 2020, time=2020-11-29, status=1, ipAttribution=)]

2021-06-27 宋威

#小分子#

85 0

[GetPortalCommentsPageByObjectIdResponse(id=1794227, encodeId=435d1e94227f4, content=<a href='/topic/show?id=e6501655420' target=_blank style='color:#2F92EE;'>#Sosei#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16554, encryptionId=e6501655420, topicName=Sosei)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Apr 16 12:15:17 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914709, encodeId=e7c31914e096a, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sun Jun 27 03:15:17 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294588, encodeId=e212129458869, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591536, encodeId=c23e159153699, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903591, encodeId=2e9c903591b5, content=<a href='/topic/show?id=65b05806579' target=_blank style='color:#2F92EE;'>#新冠病毒#</a> <a href='/topic/show?id=d61d32384ef' target=_blank style='color:#2F92EE;'>#制药#</a> 日本制药公司Sosei早在4月就启动了研发计划，旨在设计和开发针对SARS-CoV-2病毒的新型药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=234, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58065, encryptionId=65b05806579, topicName=新冠病毒), TopicDto(id=32384, encryptionId=d61d32384ef, topicName=制药)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Mon Nov 30 17:10:00 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903287, encodeId=399990328e6b, content=想学习想学习想学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Nov 29 14:38:48 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903276, encodeId=7e479032e65e, content=打败新冠，共同进步。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/928bf083b196415cbaa5a8292d70e333/cdfe5f3f34794434be595ee70b8766e8.jpg, createdBy=69a95401355, createdName=ms9000001235733856, createdTime=Sun Nov 29 14:35:34 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903265, encodeId=05e390326555, content=希望有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/b5cbbe56f416461784f4cd3a1f07fac9/5dfb1f9c9f4c4d7f8d5f82b96a120488.jpg, createdBy=e4702774429, createdName=18327144a0m, createdTime=Sun Nov 29 14:12:18 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903233, encodeId=a8a4903233c1, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sun Nov 29 11:19:04 CST 2020, time=2020-11-29, status=1, ipAttribution=)]

2020-12-01 chentianping

#日本#

78 0

[GetPortalCommentsPageByObjectIdResponse(id=1794227, encodeId=435d1e94227f4, content=<a href='/topic/show?id=e6501655420' target=_blank style='color:#2F92EE;'>#Sosei#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16554, encryptionId=e6501655420, topicName=Sosei)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Apr 16 12:15:17 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914709, encodeId=e7c31914e096a, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sun Jun 27 03:15:17 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294588, encodeId=e212129458869, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591536, encodeId=c23e159153699, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903591, encodeId=2e9c903591b5, content=<a href='/topic/show?id=65b05806579' target=_blank style='color:#2F92EE;'>#新冠病毒#</a> <a href='/topic/show?id=d61d32384ef' target=_blank style='color:#2F92EE;'>#制药#</a> 日本制药公司Sosei早在4月就启动了研发计划，旨在设计和开发针对SARS-CoV-2病毒的新型药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=234, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58065, encryptionId=65b05806579, topicName=新冠病毒), TopicDto(id=32384, encryptionId=d61d32384ef, topicName=制药)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Mon Nov 30 17:10:00 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903287, encodeId=399990328e6b, content=想学习想学习想学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Nov 29 14:38:48 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903276, encodeId=7e479032e65e, content=打败新冠，共同进步。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/928bf083b196415cbaa5a8292d70e333/cdfe5f3f34794434be595ee70b8766e8.jpg, createdBy=69a95401355, createdName=ms9000001235733856, createdTime=Sun Nov 29 14:35:34 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903265, encodeId=05e390326555, content=希望有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/b5cbbe56f416461784f4cd3a1f07fac9/5dfb1f9c9f4c4d7f8d5f82b96a120488.jpg, createdBy=e4702774429, createdName=18327144a0m, createdTime=Sun Nov 29 14:12:18 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903233, encodeId=a8a4903233c1, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sun Nov 29 11:19:04 CST 2020, time=2020-11-29, status=1, ipAttribution=)]

2020-12-01 xlwang2697

#制药公司#

92 0

[GetPortalCommentsPageByObjectIdResponse(id=1794227, encodeId=435d1e94227f4, content=<a href='/topic/show?id=e6501655420' target=_blank style='color:#2F92EE;'>#Sosei#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16554, encryptionId=e6501655420, topicName=Sosei)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Apr 16 12:15:17 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914709, encodeId=e7c31914e096a, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sun Jun 27 03:15:17 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294588, encodeId=e212129458869, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591536, encodeId=c23e159153699, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903591, encodeId=2e9c903591b5, content=<a href='/topic/show?id=65b05806579' target=_blank style='color:#2F92EE;'>#新冠病毒#</a> <a href='/topic/show?id=d61d32384ef' target=_blank style='color:#2F92EE;'>#制药#</a> 日本制药公司Sosei早在4月就启动了研发计划，旨在设计和开发针对SARS-CoV-2病毒的新型药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=234, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58065, encryptionId=65b05806579, topicName=新冠病毒), TopicDto(id=32384, encryptionId=d61d32384ef, topicName=制药)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Mon Nov 30 17:10:00 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903287, encodeId=399990328e6b, content=想学习想学习想学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Nov 29 14:38:48 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903276, encodeId=7e479032e65e, content=打败新冠，共同进步。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/928bf083b196415cbaa5a8292d70e333/cdfe5f3f34794434be595ee70b8766e8.jpg, createdBy=69a95401355, createdName=ms9000001235733856, createdTime=Sun Nov 29 14:35:34 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903265, encodeId=05e390326555, content=希望有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/b5cbbe56f416461784f4cd3a1f07fac9/5dfb1f9c9f4c4d7f8d5f82b96a120488.jpg, createdBy=e4702774429, createdName=18327144a0m, createdTime=Sun Nov 29 14:12:18 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903233, encodeId=a8a4903233c1, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sun Nov 29 11:19:04 CST 2020, time=2020-11-29, status=1, ipAttribution=)]

2020-11-30 BJying

#新冠病毒# #制药# 日本制药公司Sosei早在4月就启动了研发计划，旨在设计和开发针对SARS-CoV-2病毒的新型药物。

234 0

[GetPortalCommentsPageByObjectIdResponse(id=1794227, encodeId=435d1e94227f4, content=<a href='/topic/show?id=e6501655420' target=_blank style='color:#2F92EE;'>#Sosei#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16554, encryptionId=e6501655420, topicName=Sosei)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Apr 16 12:15:17 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914709, encodeId=e7c31914e096a, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sun Jun 27 03:15:17 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294588, encodeId=e212129458869, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591536, encodeId=c23e159153699, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903591, encodeId=2e9c903591b5, content=<a href='/topic/show?id=65b05806579' target=_blank style='color:#2F92EE;'>#新冠病毒#</a> <a href='/topic/show?id=d61d32384ef' target=_blank style='color:#2F92EE;'>#制药#</a> 日本制药公司Sosei早在4月就启动了研发计划，旨在设计和开发针对SARS-CoV-2病毒的新型药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=234, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58065, encryptionId=65b05806579, topicName=新冠病毒), TopicDto(id=32384, encryptionId=d61d32384ef, topicName=制药)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Mon Nov 30 17:10:00 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903287, encodeId=399990328e6b, content=想学习想学习想学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Nov 29 14:38:48 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903276, encodeId=7e479032e65e, content=打败新冠，共同进步。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/928bf083b196415cbaa5a8292d70e333/cdfe5f3f34794434be595ee70b8766e8.jpg, createdBy=69a95401355, createdName=ms9000001235733856, createdTime=Sun Nov 29 14:35:34 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903265, encodeId=05e390326555, content=希望有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/b5cbbe56f416461784f4cd3a1f07fac9/5dfb1f9c9f4c4d7f8d5f82b96a120488.jpg, createdBy=e4702774429, createdName=18327144a0m, createdTime=Sun Nov 29 14:12:18 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903233, encodeId=a8a4903233c1, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sun Nov 29 11:19:04 CST 2020, time=2020-11-29, status=1, ipAttribution=)]

2020-11-29 陈小凤

想学习想学习想学习

128 0

[GetPortalCommentsPageByObjectIdResponse(id=1794227, encodeId=435d1e94227f4, content=<a href='/topic/show?id=e6501655420' target=_blank style='color:#2F92EE;'>#Sosei#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16554, encryptionId=e6501655420, topicName=Sosei)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Apr 16 12:15:17 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914709, encodeId=e7c31914e096a, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sun Jun 27 03:15:17 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294588, encodeId=e212129458869, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591536, encodeId=c23e159153699, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903591, encodeId=2e9c903591b5, content=<a href='/topic/show?id=65b05806579' target=_blank style='color:#2F92EE;'>#新冠病毒#</a> <a href='/topic/show?id=d61d32384ef' target=_blank style='color:#2F92EE;'>#制药#</a> 日本制药公司Sosei早在4月就启动了研发计划，旨在设计和开发针对SARS-CoV-2病毒的新型药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=234, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58065, encryptionId=65b05806579, topicName=新冠病毒), TopicDto(id=32384, encryptionId=d61d32384ef, topicName=制药)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Mon Nov 30 17:10:00 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903287, encodeId=399990328e6b, content=想学习想学习想学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Nov 29 14:38:48 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903276, encodeId=7e479032e65e, content=打败新冠，共同进步。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/928bf083b196415cbaa5a8292d70e333/cdfe5f3f34794434be595ee70b8766e8.jpg, createdBy=69a95401355, createdName=ms9000001235733856, createdTime=Sun Nov 29 14:35:34 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903265, encodeId=05e390326555, content=希望有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/b5cbbe56f416461784f4cd3a1f07fac9/5dfb1f9c9f4c4d7f8d5f82b96a120488.jpg, createdBy=e4702774429, createdName=18327144a0m, createdTime=Sun Nov 29 14:12:18 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903233, encodeId=a8a4903233c1, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sun Nov 29 11:19:04 CST 2020, time=2020-11-29, status=1, ipAttribution=)]

2020-11-29 ms9000001235733856

打败新冠，共同进步。。

128 0

[GetPortalCommentsPageByObjectIdResponse(id=1794227, encodeId=435d1e94227f4, content=<a href='/topic/show?id=e6501655420' target=_blank style='color:#2F92EE;'>#Sosei#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16554, encryptionId=e6501655420, topicName=Sosei)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Apr 16 12:15:17 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914709, encodeId=e7c31914e096a, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sun Jun 27 03:15:17 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294588, encodeId=e212129458869, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591536, encodeId=c23e159153699, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903591, encodeId=2e9c903591b5, content=<a href='/topic/show?id=65b05806579' target=_blank style='color:#2F92EE;'>#新冠病毒#</a> <a href='/topic/show?id=d61d32384ef' target=_blank style='color:#2F92EE;'>#制药#</a> 日本制药公司Sosei早在4月就启动了研发计划，旨在设计和开发针对SARS-CoV-2病毒的新型药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=234, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58065, encryptionId=65b05806579, topicName=新冠病毒), TopicDto(id=32384, encryptionId=d61d32384ef, topicName=制药)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Mon Nov 30 17:10:00 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903287, encodeId=399990328e6b, content=想学习想学习想学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Nov 29 14:38:48 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903276, encodeId=7e479032e65e, content=打败新冠，共同进步。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/928bf083b196415cbaa5a8292d70e333/cdfe5f3f34794434be595ee70b8766e8.jpg, createdBy=69a95401355, createdName=ms9000001235733856, createdTime=Sun Nov 29 14:35:34 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903265, encodeId=05e390326555, content=希望有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/b5cbbe56f416461784f4cd3a1f07fac9/5dfb1f9c9f4c4d7f8d5f82b96a120488.jpg, createdBy=e4702774429, createdName=18327144a0m, createdTime=Sun Nov 29 14:12:18 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903233, encodeId=a8a4903233c1, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sun Nov 29 11:19:04 CST 2020, time=2020-11-29, status=1, ipAttribution=)]

2020-11-29 18327144a0m

希望有效

112 0

[GetPortalCommentsPageByObjectIdResponse(id=1794227, encodeId=435d1e94227f4, content=<a href='/topic/show?id=e6501655420' target=_blank style='color:#2F92EE;'>#Sosei#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16554, encryptionId=e6501655420, topicName=Sosei)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Apr 16 12:15:17 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914709, encodeId=e7c31914e096a, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sun Jun 27 03:15:17 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294588, encodeId=e212129458869, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591536, encodeId=c23e159153699, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Tue Dec 01 02:15:17 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903591, encodeId=2e9c903591b5, content=<a href='/topic/show?id=65b05806579' target=_blank style='color:#2F92EE;'>#新冠病毒#</a> <a href='/topic/show?id=d61d32384ef' target=_blank style='color:#2F92EE;'>#制药#</a> 日本制药公司Sosei早在4月就启动了研发计划，旨在设计和开发针对SARS-CoV-2病毒的新型药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=234, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58065, encryptionId=65b05806579, topicName=新冠病毒), TopicDto(id=32384, encryptionId=d61d32384ef, topicName=制药)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Mon Nov 30 17:10:00 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903287, encodeId=399990328e6b, content=想学习想学习想学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Nov 29 14:38:48 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903276, encodeId=7e479032e65e, content=打败新冠，共同进步。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/928bf083b196415cbaa5a8292d70e333/cdfe5f3f34794434be595ee70b8766e8.jpg, createdBy=69a95401355, createdName=ms9000001235733856, createdTime=Sun Nov 29 14:35:34 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903265, encodeId=05e390326555, content=希望有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/b5cbbe56f416461784f4cd3a1f07fac9/5dfb1f9c9f4c4d7f8d5f82b96a120488.jpg, createdBy=e4702774429, createdName=18327144a0m, createdTime=Sun Nov 29 14:12:18 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903233, encodeId=a8a4903233c1, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sun Nov 29 11:19:04 CST 2020, time=2020-11-29, status=1, ipAttribution=)]

2020-11-29 355366180

不错

125 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

感染

日本制药公司Sosei Heptares发现或可治疗COVID-19的小分子

相关资讯

拓展阅读

科室

工具

服务